Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

By G. Scagliotti, P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, P. Serwatowski, U. Gatzemeier, R. Digumarti, M. Zukin and 10 more. Journal of Clinical Oncology, 2008

3,145 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/3f1eca6920ead93f94610b1beaa71e35198261b8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, positive): “• Pemetrexed-based combination ChT represents a therapeutic option, based on the results of a recent meta-analysis that showed a slight but significant survival benefit compared with gemcitabine- or docetaxel-based combinations and of a pre-planned subgroup analysis of a large randomised phase III t”
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, background): “94) Less grade 3+ toxicity neutropenia anaemia thrombocytopenia 4 [84]”
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer (2018, positive): “Because EGFR mutations are detected mostly in patients with an adenocarcinoma or non-squamous histology, the optimum regimen might be pemetrexed and platinum combination treatment [81], followed by maintenance pemetrexed for patients who did not suffer from disease progression [48, 82].”
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. (2012, background): “The 130-nm albumin-bound formulation of paclitaxel (nabpaclitaxel [Abraxane]; Celgene, Summit, NJ) is a promising new agent for all histologies of NSCLC. Preclinical models suggest that nab- paclitaxel may reach the tumor microenvironment more efficiently than sb-paclitaxel via caveolae-mediated tra”
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer (2012, positive): “Non-small cell lung cancer (NSCLC) is increasingly recognized as a heterogeneous set of diseases at the molecular level and these differences can drive therapeutic decision-making (1-3).”
Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images (2017, background): “For the purpose of this study, we analyze 1520 H&E stained whole-slide histopathology images as well as 1629 H&E stained high resolution image patches (40 × magniﬁcation) of two TCGA lung cancer subtypes (i.e., LUAD versus LUSC).”